These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

398 related articles for article (PubMed ID: 34787281)

  • 1. Potential kidney damage associated with the use of remdesivir for COVID-19: analysis of a pharmacovigilance database.
    Silva NAO; Zara ALSA; Figueras A; Melo DO
    Cad Saude Publica; 2021; 37(10):e00077721. PubMed ID: 34787281
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Remdesivir and Acute Renal Failure: A Potential Safety Signal From Disproportionality Analysis of the WHO Safety Database.
    Gérard AO; Laurain A; Fresse A; Parassol N; Muzzone M; Rocher F; Esnault VLM; Drici MD
    Clin Pharmacol Ther; 2021 Apr; 109(4):1021-1024. PubMed ID: 33340409
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Acute renal failure and cardiac arrhythmias associated with remdesivir use in patients with COVID-19 infections: Analysis using the US FDA adverse event reporting system.
    Orogun L; Chyou TY; Nishtala PS
    Int J Risk Saf Med; 2023; 34(2):87-99. PubMed ID: 37154187
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Psychiatric Disorders and Hydroxychloroquine for Coronavirus Disease 2019 (COVID-19): A VigiBase Study.
    Garcia P; Revet A; Yrondi A; Rousseau V; Degboe Y; Montastruc F
    Drug Saf; 2020 Dec; 43(12):1315-1322. PubMed ID: 33078372
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Assessment of adverse events associated with remdesivir use for coronavirus disease 2019 using real-world data.
    Singh A; Kamath A
    Expert Opin Drug Saf; 2021 Dec; 20(12):1559-1564. PubMed ID: 34328807
    [No Abstract]   [Full Text] [Related]  

  • 6. Association of Antiviral Drugs for the Treatment of COVID-19 With Acute Renal Failure.
    Kamo M; Sogawa R; Shimanoe C
    In Vivo; 2024; 38(4):1841-1846. PubMed ID: 38936945
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Acute Kidney Injury and Drugs Prescribed for COVID-19 in Diabetes Patients: A Real-World Disproportionality Analysis.
    Zhou Y; Li J; Wang L; Zhu X; Zhang M; Zheng J
    Front Pharmacol; 2022; 13():833679. PubMed ID: 35370750
    [No Abstract]   [Full Text] [Related]  

  • 8. Adverse effects of remdesivir, hydroxychloroquine and lopinavir/ritonavir when used for COVID-19: systematic review and meta-analysis of randomised trials.
    Izcovich A; Siemieniuk RA; Bartoszko JJ; Ge L; Zeraatkar D; Kum E; Qasim A; Khamis AM; Rochwerg B; Agoritsas T; Chu DK; McLeod SL; Mustafa RA; Vandvik P; Brignardello-Petersen R
    BMJ Open; 2022 Mar; 12(3):e048502. PubMed ID: 35236729
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hepatobiliary Adverse Drug Reactions Associated With Remdesivir: The WHO International Pharmacovigilance Study.
    Kim MS; Jung SY; Lee SW; Li H; Koyanagi A; Kronbichler A; Dragioti E; Tizaoui K; Wasuwanich P; Hong SH; Ghayda RA; Yoo HW; Kim H; Jacob L; Salem JE; Kostev K; Shin YH; Kim SY; Gamerith G; Yon DK; Shin JI; Smith L
    Clin Gastroenterol Hepatol; 2021 Sep; 19(9):1970-1972.e3. PubMed ID: 33940227
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cardiovascular events and safety outcomes associated with remdesivir using a World Health Organization international pharmacovigilance database.
    Jung SY; Kim MS; Li H; Lee KH; Koyanagi A; Solmi M; Kronbichler A; Dragioti E; Tizaoui K; Cargnin S; Terrazzino S; Hong SH; Abou Ghayda R; Kim NK; Chung SK; Jacob L; Salem JE; Yon DK; Lee SW; Kostev K; Kim AY; Jung JW; Choi JY; Shin JS; Park SJ; Choi SW; Ban K; Moon SH; Go YY; Shin JI; Smith L
    Clin Transl Sci; 2022 Feb; 15(2):501-513. PubMed ID: 34719115
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Acute Kidney Injury Associated With Remdesivir: A Comprehensive Pharmacovigilance Analysis of COVID-19 Reports in FAERS.
    Wu B; Luo M; Wu F; He Z; Li Y; Xu T
    Front Pharmacol; 2022; 13():692828. PubMed ID: 35401177
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Remdesivir in the COVID-19 Pandemic: An Analysis of Spontaneous Reports in VigiBase During 2020.
    Rocca E; Gauffin O; Savage R; Vidlin SH; Grundmark B
    Drug Saf; 2021 Sep; 44(9):987-998. PubMed ID: 34374967
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Remdesivir for COVID-19 and acute kidney injury: disproportionality analysis of data from the U.S. Food and Drug Administration Adverse Event Reporting System.
    Li X; Zhou L; Gaggl M; Kinlaw AC; Gou Z; Xu Y; Wei J; Wang T
    Int J Clin Pharm; 2023 Apr; 45(2):509-514. PubMed ID: 36964312
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A prospective, observational study to evaluate adverse drug reactions in patients with COVID-19 treated with remdesivir or hydroxychloroquine: a preliminary report.
    Falcão F; Viegas E; Carmo I; Soares J; Falcao M; Solano M; Cavaco P; Mendes D; Rijo J; Povoa P; Pais Martins A; Carmo E; Mansinho K; Fonseca C; Campos L; Carvalho A; Mirco A; Farinha H; Aldir I; Correia J
    Eur J Hosp Pharm; 2021 Sep; 28(5):248-253. PubMed ID: 33452110
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serious bradycardia and remdesivir for coronavirus 2019 (COVID-19): a new safety concerns.
    Touafchia A; Bagheri H; Carrié D; Durrieu G; Sommet A; Chouchana L; Montastruc F
    Clin Microbiol Infect; 2021 Feb; 27(5):791.e5-8. PubMed ID: 33647441
    [TBL] [Abstract][Full Text] [Related]  

  • 16. SARS-CoV-2: Recent Reports on Antiviral Therapies Based on Lopinavir/Ritonavir, Darunavir/Umifenovir, Hydroxychloroquine, Remdesivir, Favipiravir and other Drugs for the Treatment of the New Coronavirus.
    Costanzo M; De Giglio MAR; Roviello GN
    Curr Med Chem; 2020; 27(27):4536-4541. PubMed ID: 32297571
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Drug-induced liver injury associated with lopinavir-ritonavir in patients with COVID-19: a disproportionality analysis of U.S. food and drug administration adverse event reporting system (FAERS) data.
    Tang H; Zhou L; Li X; Kinlaw AC; Yang JY; Moon AM; Barnes EL; Wang T
    Int J Clin Pharm; 2021 Aug; 43(4):1116-1122. PubMed ID: 34328585
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sex Differences in Reported Adverse Drug Reactions to COVID-19 Drugs in a Global Database of Individual Case Safety Reports.
    Zekarias A; Watson S; Vidlin SH; Grundmark B
    Drug Saf; 2020 Dec; 43(12):1309-1314. PubMed ID: 32978702
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Drug-Associated Acute Kidney Injury Identified in the United States Food and Drug Administration Adverse Event Reporting System Database.
    Welch HK; Kellum JA; Kane-Gill SL
    Pharmacotherapy; 2018 Aug; 38(8):785-793. PubMed ID: 29883524
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety profile of COVID-19 drugs in a real clinical setting.
    Chiu MN; Bhardwaj M; Sah SP
    Eur J Clin Pharmacol; 2022 May; 78(5):733-753. PubMed ID: 35088108
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.